All In Biotech

Drug Trial Radar · NCT00289991

Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 489 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

489

Actual

Start

Mar 2006

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.

Conditions

  • Antifungal Prophylaxis of Invasive Fungal Infections

Interventions

  • ItraconazoleDrug

    Prophylaxis

  • Vfend - voriconazoleDrug

    Prophylaxis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success at Day 180: Percent of Responders (Randomization Strata)Time frame: Day 180 (Visit 9)

Locations

49 sites in 12 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Vancouver, British Columbia, Canada

  • Pfizer Investigational Site

    Winnipeg, Manitoba, Canada

  • Pfizer Investigational Site

    Winnipeg, Manitoba, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

  • Pfizer Investigational Site

    Bmo, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Cairo, Egypt

  • Pfizer Investigational Site

    Caen, France

  • Pfizer Investigational Site

    Créteil, France

  • Pfizer Investigational Site

    Paris, France

  • Pfizer Investigational Site

    Pessac, France

  • Pfizer Investigational Site

    Rouen, France

  • Pfizer Investigational Site

    Vandœuvre-lès-Nancy, France

  • Pfizer Investigational Site

    Villejuif, France

  • Pfizer Investigational Site

    Marseille, Cedex 09, France

  • Pfizer Investigational Site

    Athens, Greece

  • Pfizer Investigational Site

    Exohi Asvestohoriou, Thessaloniki, Greece

  • Pfizer Investigational Site

    Amman, Jordan

  • Pfizer Investigational Site

    Lisbon, Portugal

  • Pfizer Investigational Site

    Porto, Portugal

  • Pfizer Investigational Site

    Moscow, Russia

  • Pfizer Investigational Site

    Saint Petersburg, Russia

  • Pfizer Investigational Site

    Badalona, Barcelona, Spain

  • Pfizer Investigational Site

    Barcelona, Barcelona, Spain

  • Pfizer Investigational Site

    Barcelona, Barcelona, Spain

  • Pfizer Investigational Site

    Madrid, Madrid, Spain

  • Pfizer Investigational Site

    Madrid, Madrid, Spain

  • Pfizer Investigational Site

    Madrid, Madrid, Spain

  • Pfizer Investigational Site

    Salamanca, Salamanca, Spain

  • Pfizer Investigational Site

    Seville, Sevilla, Spain

  • Pfizer Investigational Site

    Valencia, Valencia, Spain

  • Pfizer Investigational Site

    Valencia, Valencia, Spain

  • Pfizer Investigational Site

    Ch-4031 Basel, Switzerland

  • Pfizer Investigational Site

    Geneva, Switzerland

  • Pfizer Investigational Site

    Ankara, Turkey (Türkiye)

  • Pfizer Investigational Site

    Kayseri, Turkey (Türkiye)

  • Pfizer Investigational Site

    Bristol, United Kingdom

  • Pfizer Investigational Site

    Cambridge, United Kingdom

  • Pfizer Investigational Site

    Cardiff, United Kingdom

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.